GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dawnrays Pharmaceutical (Holdings) Ltd (HKSE:02348) » Definitions » Revenue

Dawnrays Pharmaceutical (Holdings) (HKSE:02348) Revenue : HK$1,137 Mil (TTM As of Jun. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Dawnrays Pharmaceutical (Holdings) Revenue?

Dawnrays Pharmaceutical (Holdings)'s revenue for the six months ended in Jun. 2024 was HK$622 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2024 was HK$1,137 Mil. Dawnrays Pharmaceutical (Holdings)'s Revenue per Share for the six months ended in Jun. 2024 was HK$0.41. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.76.

Warning Sign:

Dawnrays Pharmaceutical (Holdings) Ltd revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Dawnrays Pharmaceutical (Holdings) was -18.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 2.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was 6.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was 3.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Dawnrays Pharmaceutical (Holdings)'s highest 3-Year average Revenue per Share Growth Rate was 20.60% per year. The lowest was -9.70% per year. And the median was 6.20% per year.


Dawnrays Pharmaceutical (Holdings) Revenue Historical Data

The historical data trend for Dawnrays Pharmaceutical (Holdings)'s Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dawnrays Pharmaceutical (Holdings) Revenue Chart

Dawnrays Pharmaceutical (Holdings) Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,214.20 1,426.69 1,426.81 1,259.10 1,132.06

Dawnrays Pharmaceutical (Holdings) Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 730.56 710.87 548.23 621.65 515.54

Competitive Comparison of Dawnrays Pharmaceutical (Holdings)'s Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Dawnrays Pharmaceutical (Holdings)'s Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dawnrays Pharmaceutical (Holdings)'s Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dawnrays Pharmaceutical (Holdings)'s Revenue distribution charts can be found below:

* The bar in red indicates where Dawnrays Pharmaceutical (Holdings)'s Revenue falls into.


;
;

Dawnrays Pharmaceutical (Holdings) Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$1,137 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dawnrays Pharmaceutical (Holdings)  (HKSE:02348) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Dawnrays Pharmaceutical (Holdings) Revenue Related Terms

Thank you for viewing the detailed overview of Dawnrays Pharmaceutical (Holdings)'s Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Dawnrays Pharmaceutical (Holdings) Business Description

Traded in Other Exchanges
N/A
Address
338 Hennessy Road, Units 3001-02, 30th Floor, CNT Tower, Wanchai, North Sea Centre, Hong Kong, HKG
Dawnrays Pharmaceutical (Holdings) Ltd is a drug manufacturing company. The company operates two segments, including Intermediates and Bulk Medicines, and Finished Drugs. The revenue is derived from the Finished Drugs segment. Nearly all of the company's sales are generated in Mainland China. It utilizes strategic partnerships as a component of its international strategies. The company is open to exploring potential acquisitions as a component of its overall growth plan.
Executives
Fortune United Group Limited 2101 Beneficial owner
Hunwick International Limited 2201 Interest of corporation controlled by you
Keysmart Enterprises Limited 2201 Interest of corporation controlled by you
Iu Pun 2202 Interest of your spouse
Li Tung Ming
Li Kei Ling
Hung Yung Lai
Fmr Llc 2201 Interest of corporation controlled by you
Toyo International Investment Limited
Leung Hong Man
Leung Yiu Sing
Chu Shuet Fong
Lo Mei Sai
Time Lead Investments Limited

Dawnrays Pharmaceutical (Holdings) Headlines

No Headlines